Letters, Statements and Analysis - 2013

Communicating the importance of managed care pharmacy is a key part of AMCP’s work. Using AMCP policies as a basis for their work, AMCP staff and volunteers provide comments, analysis and testimony to Congress and other federal and state agencies on how proposed regulations and laws impact managed care pharmacy and the patients we serve.

 

2017

 

2016

 

2015

 

2014

 

2013

 

 

December

12/20/13

AMCP Comments on CMS Interim Final Rule to Suspend Managed Care Tools in Marketplaces 

AMCP signs joint letter to the House and Senate Appropriations Committees encouraging strong funding for the FDA 

12/19/13

Electronic Medication Prior Authorization Coalition Informs State Legislators of New NCPDP Standards for e-PA 

12/11/13

AMCP Supports Senate Finance Committee Amendment to Recognize Pharmacists as Providers in ACOs 

AMCP Opposes MTM Expansion in Medicare Part D - HR. 1024/S. 557 

12/6/13

AMCP Opposes Medicaid Rebates for Dual Eligibles 

 

November

11/22/13

FDA Response to AMCP Letter on Biosimilar Naming Conventions Suggests it is Considering Options 

11/21/13

AMCP Proposes Modifications to Massachusetts HB 3734 Addressing Biosimilar Products 

11/11/13

AMCP Signs Joint Letter to HHS in Opposition to Rescheduling Hydrocodone Combination Products 

11/8/13

AMCP Opposes Michigan HB 4751 addressing equal cost-sharing for oral and intravenous chemotherapy treatment 

11/6/13

AMCP Letter to the World Health Organization in Support of Shared Naming for Biosimilar Products 

11/5/13

AMCP Supports Shared Naming for Interchangable Biosimilar Products in Letter to FDA 

 

October

10/30/13

AMCP Comments on Draft Medicare Model Guidelines for Formularies v6.0 

10/24/13

AMCP Recommends Modifications to Massachusetts Pharmacy Audit Legislation 

10/23/13

AMCP Facilitates Letter from Six U.S. Senators to FDA Commissioner Hamburg re: Biosimilar Naming 

10/10/13

AMCP Recommends Iowa Board of Pharmacy Rescind Unnecessary Regulatory Proposal Restricting Pharmacists' Ability to Substitute Generic Products  

10/8/13

AMCP Supports Action (H.R. 3204) to Protect the Drug Supply Chain and Asks for Modifications Concerning the Regulation of Compounding  

10/4/13

AMCP Comments on Texas Board of Pharmacy Strategic Plan 

AMCP Submits Comments to HHS on Role of Managed Care Pharmacists in Adverse Drug Prevention Strategies  

 

September

9/24/13

AMCP asks California Governor, Edmund Brown, Jr., to Sign SB 493, Establishing Provider Status for Pharmacists 

9/23/13

AMCP Sends Letter of Support for Draft Legislation Addressing a Beneficiary Protection Program in Medicare Part D 

9/6/13

AMCP asks California Governor Edmund Brown, Jr. to Veto SB 598 Addressing Biosimilar Substitution 

 

July

7/31/2013

AMCP Provides Comments to the Senate Health, Education, Labor, and Pensions Committee Regarding an amendment in the nature of a substitute to S. 959 (Pharmaceutical Compounding) 

7/26/2013

AMCP Provides Statement in Response to Food and Drug Administration Notice Standardizing and Evaluating Risk Evaluation and Mitigation Strategies 

7/18/13

AMCP Provides Comments to U.S. Representative Morgan Griffith (R-VA) concerning the "Compounding Clarity Act" Discussion Draft. 

7/10/13

AMCP Requests Delaware Governor Markell to Veto Senate Bill 35, which limits patients' copay and mandates exception process for specialty drugs. 

AMCP Summary of CMS Opioid Management System for Controlled Substance Utilization 

7/8/2013

AMCP Provides Comments to the New Jersey Assembly Committee on Financial Institutions and Insurance on Pharmacy Audits Legislation 

7/5/2013

CMS Announces Oversight Management System for Controlled Substances 

 

June

6/26/2013

AMCP Provides Comments to the Rhode Island House of Representatives Regarding Legislation That Would Provide Coverage of Orally Administered Cancer Drugs on a Basis No Less Favorable than Intravenously Administered or Injected Anticancer Medications 

AMCP Provides Comments to the Delaware House of Representatives Regarding Legislation That Would Impose A Dollar Limit on a Specialty Drug and Mandates and Exception Process 

6/24/2013

AMCP Provides Comments to the Illinois Senate Regarding Prior Authorization Procedures and Requirements 

6/21/2013

AMCP Provides Comments to the California Senate Committee on Health Regarding Imposing Additional Requirements for Health Plan or Pharmacy Benefit Manager (PBM) Step Therapy Programs  

6/20/2013

AMCP Provides Comments to the North Carolina Senate Committee on Healthcare Regarding  Equal Co-Pay for Oral Chemotherapy and Intravenous Chemotherapy 

AMCP Provides Comments to Representative Morgan Griffith (R-VA) Regarding Pharmacy Compounding Processes 

AMCP Provides Comments to Members of the Delaware Senate Regarding Placing Unnecessary Burdens on the Substitution of Biosimilars    

6/11/2013

AMCP Provides Comments to the Delaware Senate Sunset Committee on the Substitution of Biosimilars 

6/04/2013

AMCP Urges HHS to Adopt Evidence-Based Formularies for Qualified Health Plans in the Marketplaces 

6/03/2013

AMCP Provides Comments to the Louisiana House of Representatives Regarding Prior Authorization, Prescription Drug Formularies, and Step Therapy Legislation 

 

May

5/29/2013

AMCP Provides Comments to the Secretary of Health and Human Services, Kathleen Sebelius, Regarding Essential Health Benefit Reuirements 

5/28/2013

AMCP Provides Comments to the Oregon Joint Committee on Ways and Means Sub-Committee on Human Services Regarding Legislation That Would Provide for the Auditing of Pharmacy Claims 

5/14/2013

AMCP Provides Comments to the California Assembly Committee on Appropriations Regarding Imposing Additional Requirements for Health Plans or Pharmacy Benefit Manager Step Therapy Programs 

5/08/2013

AMCP Provides Comments To The Texas House of Representatives Public Health Committee Regarding Legislation Placing Unnecessary Burdens on the Substitution of Biosimilars 

AMCP Provides Comments and Requests Colorado Governor Hickenlooper Veto State  Legislation Adversely Affecting Uniform Prior Authorization of Prescription Drugs  

5/03/2013

AMCP Provides Comments to the Senate Health, Education, Labor, and Pensions Committee Regarding Draft Legislation Addressing Pharmaceutical Compounding  

5/01/2013

AMCP Sends Letter of Opposition to the Nevada State Assembly Commerce and Labor Committee Regarding Outpatient Oral Chemotherapy Agents 

 

April

4/30/2013

AMCP Sends Letter of Opposition to the California State Assembly Health Committee Regarding Imposing Additional Requirements for Health Plans or Pharmacy Benefit Manager Step Therapy Programs  

4/22/2013

AMCP Sends Letter of Opposition to the New Hampshire House of Representatives Health, Human Services, and Elderly Affairs Committee Regarding Uniform Prior Authorization of Prescription Drugs 

4/16/2013

AMCP Summary of a CMS Proposed Rule Outlining MLR Requirements for Medicare Part D and MA plans 

AMCP Submits Comments to a CMS Proposed Rule Outlining MLR Requirements for MedicarePart D and MA plans 

4/10/2013

AMCP Sends Letter of Opposition to the Oregon State Senate Committee on Health Care and Human Services Regarding Unnecessary Burdens Placed on Biosimilar Substitutions 

4/05/2013

AMCP Sends Letter of Opposition to the California State Senate Committee on Business, Professions and Economic Development Regarding Placing Unnecessary Burdens on Biosimilar Substitutions 

4/01/2013

AMCP Sends Letter of Support to the Massachusetts Joint Committee on Public Health Regarding Collaborative Drug Therapy Management 

 

March

3/26/2013

AMCP Requests Governor Dalrymple Veto Senate bill 2190, Regarding the Substitution of Biosimilars  

AMCP Sends Letter of Opposition to the Nevada Senate Committee on Commerce, Labor, and Energy Regarding Outpatient Oral Chemotherapy Agents 

3/20/2013

AMCP Sends Letter of Opposition to the North Dakota House of Representatives Regarding Placing Unnecessary Burdens on Biosimilars 

3/19/2013

AMCP Sends Senate Letter Suggesting Efforts Towards Reducing the Federal Budget Deficit 

AMCP Sends Joint Letter to the Senate Opposing Restrictionson Government Employees Who Can Attend Meetings and Conferences 

3/18/2013

AMCP Sends House of Representatives Letter Suggesting Efforts for Reducing the Federal Budget Deficit 

3/14/2013

AMCP Sends Letter of Opposition to Maryland's Health and Government Operations Committee Regarding the Substitution of Biosimilars 

3/12/2013

AMCP Sends Letter of Support to Senator Klobuchar Regarding the Prohibition of Generic Exclusion Agreements 

AMCP Sends Letter of Opposition to Maryland's Senate Finance Committee Regarding Specialty Drugs 

3/4/13

AMCP Sends Comment Letter to Texas House of Representatives regarding HB 1032 addressing Uniform Prior Authorization 

3/1/13

AMCP comments on CMS 2014 Draft Call Letter 

 

February

2/28/13

AMCP sends letter of opposition to the Oregon General Assembly regarding SB 2705 addressing biosimilars 

2/26/2013

AMCP Sends Letter of Opposition to Maryland's House of Delegates Regarding Specialty Drugs Legislation 

2/21/2013

HHS Finalizes Rule for Prescription Drug Benefit Design underEssential Health Benefits to Implement Affordable Care Act Provisions and ClarifiesPreventive Coverage for Certain OTC Items 

2/11/2013   

AMCP Sends Comment Letter to Senate Majority Leader Reid and Minority Leader McConnell on Deficit Reduction 

AMCP Sends Comment Letter to Speaker Boehner and Ranking Member Pelosi on Deficit Reduction  

2/6/2013

HHS Issues Proposal for Accommodations for Religious Organizations that Object to Provision of Contraception 

2/01/2013

Health and Human Services Details Impact of Sequester in Letter to Senator Mikulski 

 

January

1/28/2013

AMCP Sends Letter to Virginia State Senator Martin in Opposition to Biosimilars Substitution Legislation  

1/09/2013

AMCP Sends Letter to Massachusetts Gov. Deval Patrick on Chemotherapy Parity Bill 

1/04/2013

AMCP Comments on Health Care Quality in the Exchanges 

Content for class "break" Goes Here